Assessment of HIV Remission Upon cART Interruption in Early Treated Individuals Carrying the MHC B35/53Bw4TTC2 Genotype

Inclusion Criteria:

• Aged 18 years at the time of consent
• Enrolled and currently followed in a site of the ANRS CO6 PRIMO Cohort
• With the MHC genotype: at least one HLA B35 or B53 allele AND one HLA-A or B allelecarrying the Bw4 epitope AND homozygous -21T residue in the HLA-B alleles ANDheterozygous or homozygous for C2 epitope-carrying HLA-C alleles
• Treated with cART within 3 months following inclusion in ANRS CO6 Primo Cohort duringat least 18 months and cART not modified in the last 3 months
• Controlled on cART: > 90% of VL below 50 cp/mL after initial virological response
• All VL below 50 cp/mL during the previous 12 months
• Most recent CD4 measurement on cART above 500 cells/mm3
• Written and informed consent signed by the person and the investigator (no later thanthe day of pre-inclusion and prior to any examination realized in the frame of thestudy (article L1122-1-1 of the Public Health Code)
• Person affiliated or beneficiary of a social security scheme (article L1121-11 of thePublic Health Code) (State Medical Aid or AME is not a social security scheme)
• Patient agreeing to participate in the trial according to the defined procedures.

Exclusion Criteria:

• One VL above 1000 cp/mL on or off antitretrovirals after the initial viral control onantiretrovirals was achieved.
• Patient on long-acting injectable HIV treatment
• Patient in whom condom sex use or PrEP use by the partner will be difficult orimpossible.
• Woman with a pregnancy project and pregnant woman.
• Patient under guardianship or curatorship.
• History of a clinical AIDS event or cancer.
• Active HCV or HBV infection.
• Any symptoms or laboratory values suggesting a systemic disorder (renal, hepatic,cardiovascular, pulmonary) or other medical conditions, related to HIV or not, whichcontraindicates the interruption of ARVs.
• Recent SARS-CoV-2 infection and / or associated with a drop in CD4 and / or associatedwith a resumption of CV in the last 6 months. In this situation, wait until the CD4has returned to a rate > 500/mm3 and a CV < 50 copies / mL consolidated for > 6months.
• Affection, disability, resulting from a SARS-CoV-2 infection, regardless of theduration of the SARS-CoV-2 infection.
• Patient participating in another research evaluating other treatments with anexclusion period ongoing at the screening visit.
• Planned absence which could prevent optimal trial participation (vacation abroad,moving, imminent job change ...).